

VCBeat Health Contact Us

China Healthcare Select

Vertical Industries 

Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory

Home Dizal's Sunvozertinib New Indication for First-Line EGFR Exon20ins NSCLC Enters CDE Priority Review

Dizal's Sunvozertinib New Indication for First-Line EGFR Exon20ins NSCLC Enters CDE Priority Review

May 19, 2026 11:32 CST Updated 16:49

Share:

Dizal

Innovative Biopharmaceutical R&D Developer

vcbeatglobal@vcbeat.net 

SERVICES

Partnership Development Market Entry Advisory Ecosystem Engagement Advisory

COMPANY

About VCBeat Why VCBeat Contact Us

CHANNELS

China Healthcare Select Insights MNC China Lens Events VB100 GMPC

MORE

PRIVACY VCBEAT CHINA

© 2025 VCBeat. All rights reserved.